Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — President Biden’s vision for an ambitious new government research center is never quite the same. He’s said it will focus on diabetes and Alzheimer’s. He told a prominent ALS advocate that the agency would focus on his disease, too. Once, he mentioned obesity. And, of course, there is his most common refrain: that the new research branch will “end cancer as we know it.”

The shifting vision is creating a lobbying frenzy among patient advocacy groups frustrated with the pace of research, all now scrambling to ensure they benefit from the gold rush of new research dollars and high-profile attention.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment